CDC conducted a formal risk assessment of highly pathogenic influenza A H5N6 viruses in April and determined that these viruses posed a moderate risk in terms of their potential to cause a pandemic as well as the potential to cause moderate public health impact if they were to spread person-to-person. Since the first identification of human infections with influenza A H5N6 viruses in , multiple H5 CVVs have been developed to cover different antigenic groups of these viruses.
A new risk assessment of influenza A H5N6 is currently underway. Analysis of influenza A H5N6 viruses also shows that these viruses remain susceptible to influenza antiviral medications, such as the neuraminidase inhibitors oseltamivir, zanamivir, peramivir and polymerase acidic PA protein inhibitor baloxavir , meaning that treatment options would be available.
Since when the first influenza A H5N6 infection in a person was detected in China, 51 such infections have been reported, including 25 during , as of October 29, Twenty-four of the 25 cases identified in were detected in China and one was detected in Lao PDR. Most of the cases of influenza A H5N6 reported in China during have had exposure to birds prior to illness onset.
The three newest infections occurred in adults who, as of October 29, , were reportedly hospitalized or in critical condition. There have been seven deaths all in China from influenza A H5N6 this year.
As of October 29, , of the 51 laboratory-confirmed cases of human infection with influenza A H5N6 virus reported to the World Health Organization since , 25 infections resulted in death. Avian influenza is a disease caused by infection with type A bird flu viruses. These viruses occur naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species.
Bird flu viruses do not normally infect humans. While there are little data to date, most of the H3N2 viruses so far are genetically closely related to the vaccine virus, but there are some antigenic differences that have developed as H3N2 viruses have continued to evolve.
Virus antigenic data will be reported later this season when a sufficient number of specimens have been tested. CDC genetically characterized influenza viruses collected October 3, to present:.
CDC assesses susceptibility of influenza viruses to the antiviral medications including the neuraminidase inhibitors oseltamivir, zanamivir, and peramivir and the PA endonuclease inhibitor baloxavir using next generation sequence analysis supplemented by laboratory assays. Information about antiviral susceptibility test methods can be found at U. Viruses collected in the United States since October 3, , were tested for antiviral susceptibility as follows:. High levels of resistance to the adamantanes amantadine and rimantadine persist among influenza A H1N1 pdm09 and influenza A H3N2 viruses the adamantanes are not effective against influenza B viruses.
Therefore, use of these antivirals for treatment and prevention of influenza A virus infection is not recommended and data from adamantane resistance testing are not presented. The U. Outpatient Influenza-like Illness Surveillance Network ILINet monitors outpatient visits for influenza-like illness [ILI fever plus cough or sore throat ], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms such as influenza, SARS-CoV-2, and RSV.
Due to the COVID pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.
Nationwide, during week 52, 4. This percentage is above the national baseline. All 10 HHS regions are above their region-specific baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.
Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete. LTCFs e. During week 52, 1. Additional information about long-term care facility surveillance: Surveillance Methods Additional Data external icon.
FluSurv-NET hospitalization data are preliminary. Case counts and rates for recent hospital admissions are subject to reporting delays; these delays are likely to be more pronounced around holidays. As hospitalization data are received each week, prior case counts and rates are updated accordingly. As such, end-of-season rates for any given week may vary substantially from in-season reported rates.
A total of laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, , and January 1, The overall cumulative hospitalization rate was 2. This cumulative hospitalization rate is higher than the cumulative in-season hospitalization rate observed in week 52 during the season 0. Among hospitalizations, View Full Screen. Hospitals report to HHS-Protect the number of patients admitted with laboratory-confirmed influenza.
During week 52, 2, patients with laboratory-confirmed influenza were admitted to the hospital. This percentage is above the epidemic threshold of 6. The data presented are preliminary and may change as more data are received and processed.
A total of two influenza-associated pediatric deaths occurring during the season have been reported to CDC. Additional pediatric mortality surveillance information for current and past seasons: Surveillance Methods FluView Interactive.
FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information.
Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links. To receive weekly email updates about Seasonal Flu, enter your email address:.
Learn the symptoms of flu. Prescription medications called antiviral drugs can be used to treat flu. Laboratory confirmed flu activity as reported by clinical laboratories remains low.
Find flu vaccines in your area. Everyone 6 months of age and older needs a flu vaccine. Other Types of Influenza. Stay Connected with Flu. Links with this icon indicate that you are leaving the CDC website.
0コメント